FDA grants breakthrough device status to Freenome's lung cancer blood test

Go back to FDA grants breakthrough device status to Freenome's lung cancer blood test
(NASDAQ: FRNM) Delayed: 15.99 -0.32 (1.96%)
Previous Close $16.31    52 Week High
Open $16.74    52 Week Low
Day High $16.74    P/E N/A 
Day Low $15.79    EPS
Volume 506,098